Zum Artikel

Marco Winzer Partner

Marco WinzerPartner

Marco Winzer

Partner

About me

Team Life Sciences & Chemistry, Partner
at HTGF since 2005

CV

Marco Winzer has been with High-Tech Gründerfonds since its foundation and has helped to establish the fund. The economics graduate has many years of experience in financing start-ups in the life sciences industry and has supported a number of start-ups all along the value chain of the ‘Venture Capital Model’ – from seed financing to successful exit. Before working for HTGF, the Partner acquired expertise in consulting start-ups and held various positions at the Business Innovation Center Kaiserslautern as well as the Technologie-Beteiligungsgesellschaft and development bank KfW.

Social Media & contact

My success stories in the HTGF portfolio

12 of 500 Companies
2016

Reactive Robotics

Rehabilitation

Reactive Robotics is a leading healthcare startup dedicated to developing innovative technologies and solutions for the healthcare industry. The company is on a mission to revolutionize healthcare by integrating technology …

To the complete profileof Reactive Robotics
2014

Preventicus

Digital Health

Preventicus GmbH is developing smartphone-driven solutions to capture and analyze patients’ vital parameters for early preclinical risk screening of lifestyle-related illnesses. Seed funding for the Jena-based company is managed by …

To the complete profileof Preventicus
2014

AdvanceCOR

Cardiology / Cardiovascular

AdvanceCOR is a drug-developing biotech company which focuses on personalized medicine in cardiovascular diseases. We concentrate on innovative biologic drugs in acute vascular syndromes and have completed phase 2.

To the complete profileof AdvanceCOR
2007

Zedira

Metabolic Diseases

Zedira is a clinical stage biotech company specialized in the enzyme class of transglutaminases. Zedira performs drug discovery (e.g. celiac disease, diabetic nephropathy and thromboprophylaxis) and markets specialty reagents for …

To the complete profileof Zedira
2013

exelonix

In recent years, the IoT (Internet of Things) market has developed dynamically. New vendors brought new products in the fields of sensors, connectivity, applications and analytics to the market. Exelonix …

To the complete profileof exelonix
2011

CorTec

Neuromodulation

CorTec is a young medical engineering company focusing on innovations in the field of neurotechnology. With CorTec Brain Interchange we are developing a direct interface between brain and technology.

To the complete profileof CorTec

Guided to exit

12 of 500 Companies
2006

Corimmun

Exit
Pharmaceuticals

Corimmun is a drug-developing biotech company which focuses on personalized medicine in cardiovascular diseases. We concentrate on innovative peptide and biological drugs in indications with unmet medical needs. Exit since …

To the complete profileof Corimmun
2008

UROTEC

Exit

UroTec’s MukoCell® made of autologous, in vitro cultured mucosa cells. Only a small biopsy needs to be taken from the patient. Exit since August 2010.

To the complete profileof UROTEC
2007

SIRION Biotech

Exit
R&D Tools

SIRION BIOTECH produces genetically modified cells and is technology provider in the area of viral vector systems. The specialist in RNAi technology distributes more than 100 products and services. A …

To the complete profileof SIRION Biotech
2006

m2p-labs

Exit
Industrial Biotech

m2p-labs supplies microbioreactor systems focusing on micro fermentations and automated solutions for screening and bioprocess development. The product portfolio comprises high-throughput BioLector® micro fermentation systems, microtiter FlowerPlate® plates, and automated …

To the complete profileof m2p-labs
2011

futalis

Exit

futalis provides personalized petfood for dogs. To prevent health issues caused by feeding mistakes, each individual dog is offered a veterinary diet calculation. Based on scientific criteria, the nutritional requirements …

To the complete profileof futalis
2006

c-LEcta

Exit
Industrial Biotech

c-LEcta is a leading biotechnology company located in Leipzig, Germany. The company has established itself as a leading player in the realisation of high-value biotechnology products for regulated markets, either …

To the complete profileof c-LEcta

Recent posts

Last update 5 days ago
Zum Artikel

News

16. September 2024

Reactive Robotics: Staying on Course for Growth in the MedTech Sector with a €5 Million investment

Zum Artikel

News

20. October 2022

Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharmato Develop First-in-Class Celiac Disease Therapy

Zum Artikel

News

15. February 2022

Very Successful Exit for High-Tech Gründerfonds – Kerry acquires c-LEcta

Sirion Logo Zum Artikel

News

23. June 2021

Successful Exit for Creathor Ventures, High-Tech Gründerfonds, Bayern Kapital and KfW – PerkinElmer Agrees to Acquire Viral Vector Gene Delivery Leader SIRION Biotech

Zum Artikel

News

22. April 2021

High-tech and humanity – robotic assistance enters intensive care units

i3 Membrane Logo Zum Artikel

News

25. January 2021

i3 Membrane receives 7 figure sum for development and market launch of new separation technology for biomolecules